Is Acid Phosphatase (PAP) Still Justified in the Management of Prostatic Cancer?
- 1 January 1991
- journal article
- review article
- Published by Taylor & Francis in Acta Oncologica
- Vol. 30 (2), 169-170
- https://doi.org/10.3109/02841869109092343
Abstract
The usefulness of acid phosphatase (PAP) and prostate specific antigen (PSA) is compared. The author concludes that PSA is more sensitive, has better organ specificity, does less diurnal variations and correlates better with tumor which makes PSA superior for staging and monitoring of therapy in prostate cancer.Keywords
This publication has 6 references indexed in Scilit:
- The Role of Prostate Specific Antigen as a Tumor Marker in Men with Advanced Adenocarcinoma of the ProstateJournal of Urology, 1989
- Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. I. Untreated PatientsJournal of Urology, 1989
- The Value of Acid Phosphatase Measurements in Predicting Extraprostatic Cancer Growth before Radical ProstatectomyBritish Journal of Urology, 1988
- Prostate Specific Antigen in the Preoperative and Postoperative Evaluation of Localized Prostatic Cancer Treated with Radical ProstatectomyJournal of Urology, 1988
- Prostatic Specific Antigen and Prostatic Acid Phosphatase in the Monitoring and Staging of Patients with Prostatic CancerJournal of Urology, 1987
- An Evaluation of Prostate Specific Antigen in Prostatic CancerJournal of Urology, 1987